Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Swedish Orphan Biovitrum

BIOVFOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

Swedish Orphan Biovitrum (BIOVF) Forecast

News

Earnings Swedish Orphan Biovitrum (BIOVF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Swedish Orphan Biovitrum (OTC:BIOVF) Stock

Swedish Orphan Biovitrum Stock (OTC: BIOVF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, October 18, 2024

Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants
Vandana Singh

Thursday, August 08, 2024

Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
Vandana Singh

Monday, October 16, 2023

Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants
Vandana Singh

Monday, June 26, 2023

Sanofi, Sobi Earlier Announced ALTIVIIIO Late-breaking Data At ISTH Demonstrates Highly Effective Bleed Protection In Children With Severe Hemophilia A With Once-weekly Dosing
Charles Gross

Friday, June 09, 2023

Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
Vandana Singh

Thursday, May 25, 2023

Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
Vandana Singh

Thursday, May 11, 2023

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Chris Katje

Wednesday, May 10, 2023

European Swedish Orphan Biovitrum To Acquire CTI BioPharma For $1.7B
Vandana Singh

Tuesday, March 21, 2023

Selecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next Year
Vandana Singh

Thursday, November 10, 2022

Veru Stock Could Retrace Week's 45% Gain As FDA Panel Votes Against COVID-19 Drug
Shanthi Rexaline

Friday, November 04, 2022

Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
Vandana Singh

Tuesday, August 30, 2022

Sanofi's Hemophilia Candidate Goes Under Priority FDA Review
Vandana Singh

Monday, July 11, 2022

The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Vandana Singh
SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis
Vandana Singh

Friday, July 08, 2022

The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Vandana Singh
ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug
Vandana Singh

Wednesday, March 09, 2022

Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients
Vandana Singh

Wednesday, December 15, 2021

Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder
Vandana Singh

Friday, December 03, 2021

AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report
Vandana Singh

Wednesday, February 24, 2021

Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2021
Benzinga Insights
Barclays Downgrades Swedish Orphan Biovitrum ...
Benzinga Newsdesk

Tuesday, July 28, 2020

Sobi and Selecta Announce Closing of Previously Announced Strategic Licensing Agreement for Sel-212, a Phase 3-ready Novel Treatment for Chronic Refractory Gout
Charles Gross

Thursday, October 03, 2019

Stocks That Hit 52-Week Lows On Thursday
Lisa Levin

Monday, August 26, 2019

Stocks That Hit 52-Week Lows On Monday
Lisa Levin

Sunday, December 10, 2017

Bioverativ and Swedish Orphan Biovitrum AB Announc Study Shows Weekly Prophylactic Treatment with ELOCTATE Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia A at #ASH2017
Benzinga

Friday, May 13, 2016

Biogen, Swedish Orphan Biovitrum Announce EC Approves Alprolix for Treatment of Haemophilia B
Benzinga

Friday, October 16, 2015

Swedish Orphan Biovitrum AB Announces Approval of Xiapex by Swissmedic for Treatment of Peyronie's disease in Switzerland
Benzinga

Monday, December 22, 2014

Sobi, Auxilium Announce Xiapex Receives Positive Opinion by CHMP for Treatment of Peyronie's Disease
Benzinga

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved